Analysis of the clinical antibacterial and antituberculosis pipeline.

[1]  D. Sahm,et al.  1360. Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes , 2018, Open Forum Infectious Diseases.

[2]  M. Unemo,et al.  In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae , 2018, The Journal of antimicrobial chemotherapy.

[3]  C. Bissantz,et al.  In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam–β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model , 2018, Antimicrobial Agents and Chemotherapy.

[4]  A. Diacon,et al.  Perspectives for personalized therapy for patients with multidrug‐resistant tuberculosis , 2018, Journal of internal medicine.

[5]  G. Ippolito,et al.  Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. , 2018, The Lancet. Infectious diseases.

[6]  Mariana Castanheira,et al.  Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa , 2018, The Journal of antimicrobial chemotherapy.

[7]  P. Murumkar,et al.  Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis. , 2018, Journal of medicinal chemistry.

[8]  J. Rolain,et al.  Zidovudine: A salvage therapy for mcr-1 plasmid-mediated colistin-resistant bacterial infections? , 2018, International journal of antimicrobial agents.

[9]  John A. Robinson,et al.  A Peptidomimetic Antibiotic Interacts with the Periplasmic Domain of LptD from Pseudomonas aeruginosa. , 2018, ACS chemical biology.

[10]  M. Ouellette,et al.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. , 2017, The Lancet. Infectious diseases.

[11]  K. Bush.  Game Changers: New β-Lactamase Inhibitor Combinations Targeting Antibiotic Resistance in Gram-Negative Bacteria. , 2017, ACS infectious diseases.

[12]  M. Hackel,et al.  In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016 , 2017, Antimicrobial Agents and Chemotherapy.

[13]  U. Theuretzbacher.  Global antimicrobial resistance in Gram-negative pathogens and clinical need. , 2017, Current opinion in microbiology.

[14]  U. Theuretzbacher.  Antibiotic innovation for future public health needs. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  M. Castanheira,et al.  1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients , 2017, Open Forum Infectious Diseases.

[16]  P. Moja,et al.  Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis , 2017 .

[17]  N. Khanafer,et al.  Susceptibilities of clinical Clostridium difficile isolates to antimicrobials: a systematic review and meta-analysis of studies since 1970. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  Matteo Bassetti,et al.  Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach , 2017, Intensive Care Medicine.

[19]  M. Falagas,et al.  Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals , 2017, The Journal of antimicrobial chemotherapy.

[20]  L. Alban,et al.  Assessment of the Risk to Public Health due to Use of Antimicrobials in Pigs—An Example of Pleuromutilins in Denmark , 2017, Front. Vet. Sci..

[21]  N. Woodford,et al.  In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria , 2017, The Journal of antimicrobial chemotherapy.

[22]  I. Schalk,et al.  Bacterial Iron Uptake Pathways: Gates for the Import of Bactericide Compounds. , 2017, Journal of Medicinal Chemistry.

[23]  H. Jafri,et al.  Antibody-based therapy to combat Staphylococcus aureus infections. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[24]  K. Kazmierczak,et al.  In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014 , 2017, Journal of Clinical Microbiology.

[25]  H. Schünemann,et al.  World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update , 2017, European Respiratory Journal.

[26]  V. Mizrahi,et al.  Identification and validation of novel drug targets in Mycobacterium tuberculosis. , 2017, Drug discovery today.

[27]  B. Rehm,et al.  Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence , 2017, Front. Cell. Infect. Microbiol..

[28]  E. Kuijper,et al.  DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens , 2017, The Journal of antimicrobial chemotherapy.

[29]  G. Dantas,et al.  The rapid spread of carbapenem-resistant Enterobacteriaceae. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[30]  M. Cooper,et al.  Antibiotics in the clinical pipeline at the end of 2015 , 2016, The Journal of Antibiotics.

[31]  T. Grossman.  Tetracycline Antibiotics and Resistance. , 2016, Cold Spring Harbor perspectives in medicine.

[32]  S. Swaminathan,et al.  Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions , 2016, PLoS medicine.

[33]  Martha R. J. Clokie,et al.  Alternatives to antibiotics-a pipeline portfolio review. , 2016, The Lancet. Infectious diseases.

[34]  P. Nordmann,et al.  Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. , 2015, International journal of antimicrobial agents.

[35]  P. Nowak,et al.  Acinetobacter baumannii: biology and drug resistance - role of carbapenemases. , 2015, Folia histochemica et cytobiologica.

[36]  M. Huband,et al.  Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeae , 2014, Antimicrobial Agents and Chemotherapy.

[37]  T. Palzkill.  Metallo‐β‐lactamase structure and function , 2013, Annals of the New York Academy of Sciences.

[38]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[39]  K. Coleman.  Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. , 2011, Current opinion in microbiology.

[40]  L. Silver.  Challenges of Antibacterial Discovery , 2011, Clinical Microbiology Reviews.

[41]  A. Casadevall,et al.  Monoclonal antibody-based therapies for microbial diseases , 2009, Vaccine.

[42]  G. Yarranton,et al.  Antibodies for the treatment of bacterial infections: current experience and future prospects. , 2008, Current opinion in biotechnology.

[43]  N. Woodford,et al.  Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens , 2018, The Journal of antimicrobial chemotherapy.

[44]  K. Garey,et al.  Novel antibiotics in development to treat Clostridium difficile infection , 2017, Current opinion in gastroenterology.